Clinical and tumoral characteristics of diabetic patients with breast cancer

Authors

  • Yerelis de Armas Hernández Universidad de Ciencias Médicas de Pinar del Río. Facultad de Ciencias Médicas "Dr. Ernesto Che Guevara de la Serna"
  • Mónica Hernández Frómeta Universidad de Ciencias Médicas de Pinar del Río. Facultad de Ciencias Médicas “Dr. Ernesto Guevara de la Serna”. Pinar del Río, Cuba
  • Roilandys Peñate Delgado Universidad de Ciencias Médicas de Pinar del Río. Hospital General Docente “Abel Santamaría Cuadrado”. Pinar del Río, Cuba.
  • Kenia Roque Acanda Universidad de Ciencias Médicas de Pinar del Río. Facultad de Ciencias Médicas “Dr. Ernesto Guevara de la Serna”. Pinar del Río, Cuba
  • Isvel Zaldivar Garit Universidad de Ciencias Médicas de Pinar del Río. Facultad de Ciencias Médicas “Dr. Ernesto Guevara de la Serna”. Pinar del Río, Cuba.
  • Lucía Germán Flores Universidad de Ciencias Médicas de Pinar del Río. Policlínico Universitario “1 de Enero”. Pinar del Río, Cuba.

Keywords:

BREAST NEOPLASMS, DIABETES MELLITUS, RECEPTORS, ESTROGEN, BIOMARKERS.

Abstract

Introduction: breast cancer has a high incidence; its characteristics and association with other comorbidities arouse the interest of the scientific community.

Objective: to identify the relationship among clinical, tumoral and molecular characteristics with diabetes mellitus in patients with breast cancer.

Methods: an observational, analytical and cross-sectional study was conducted in patients with breast cancer attended Tercer Congreso Cancer Treatment Center in the period 2016-2021. The target group consisted of 116 patients. The information was collected from the medical records.

Results: an association was identified between the ages of 50 or older, the presence of hypertension and a history of ischemic heart disease with the incidence of diabetes mellitus (p<0,05). There was a predominance of patients with tumors between 2 and 5 cm (59,48 %), with a higher prevalence in diabetic women (90 %). The presence of diabetes mellitus was associated with tumor size (p<0,001), metastatic lymph node (p<0,001), with estrogen receptor and human epidermal growth factor receptor 2 subtypes. In diabetic patients the mean tumor diameter was 2,45 ± 0,7, higher than in non-diabetic patients.

Conclusions: in patients with breast cancer, the presence of diabetes mellitus was associated with tumor size, metastatic lymph nodes, as well as with molecular subtypes related to estrogen receptor and human epidermal growth factor receptor 2. Diabetic patients had a larger tumor diameter.

Downloads

Download data is not yet available.

References

1. Santalla Bertrán A. Cancer de mama. Sociedad Española de Oncología Médica. - SEOM: Sociedad Española de Oncología Médica© [Internet]. 2019 [citado 06/06/2021]. Disponible en: https://seom.org/info-sobre-el-cancer/cancer-de-mama?showall=1

2. Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. El cáncer de mama en el siglo XXI: de la detección precoz a los nuevos tratamientos. Radiología [Internet]. 2017 [citado 06/06/2021]; 59(5): 368-79. Disponible en: https://www.sciencedirect.com/science/article/pii/S0033833817301017

3. The World Bank Group Indicators [Internet]. [citado 06/06/2021]. Disponible en: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD

4. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario estadístico [Internet]. La Habana: MINSAP; 2019 [citado 06/06/2021]. Disponible en: http://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2019-ed-2020.pdf

5. Cabrera Rodríguez CA, Cabrera Nogueira GG, Marquez Remedio LE, Correa Martínez L, Mendive Martínez JL, Cabrera Rodríguez CA, et al. Cáncer de mama en mujeres pinareñas menores de 45 años, serie cronológica de 23 años. Rev Ciencias Médicas [Internet]. 2019 [citado 06/06/2021]; 23(6): 827-35. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1561-31942019000600827&lng=es&nrm=iso&tlng=pt

6. Villegas Valverde CA, Frontela Noda M, García Figueredo I. Nuevas evidencias del uso de la metformina en el tratamiento del cáncer. Rev Cubana Endocrinol [Internet]. 2016 [citado 06/06/2021]; 27(3): 80-90. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1561-29532016000300008&lng=es&nrm=iso&tlng=es

7. Hechavarría Naranjo S, Achiong Estupiñán F, Méndez Gómez H, Vega Rico O, Díaz Piñera A, Rodríguez Salvá A, Londoño Agudelo E. Caracterización clínica epidemiológica de la diabetes mellitus en dos áreas de salud. Municipio Cárdenas. 2017. Rev Méd Electrón [Internet]. 2019 [citado 06/06/2021]; 41(4): [aprox. 10 pp.]. Disponible en: http://www.revmedicaelectronica.sld.cu/index.php/rme/article/view/3155/4378

8. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol [Internet]. 2018 [citado 06/06/2021]; 6(6):E6-E15. Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30150-5/fulltext

9. Maskarinec G, Jacobs S, Song-Yi P, Haiman ChA, Setiawan VW, Wilkens LR, Le Marchand L. Type II Diabetes, Obesity, and Breast Cancer Risk: The Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev [Internet]. 2017 [citado 06/06/2021]; 26(6): 854–61. Disponible en: http://cebp.aacrjournals.org/lookup/doi/10.1158/1055-9965.EPI-16-0789

10. Ayala León SJ, Cabral F, Escalaa G, Cabral L, Ayala León M, Gauna C. Factores de riesgo cardiovascular en pacientes con cáncer de mama ¿Existe correlación con las referencias internacionales? Rev. virtual Soc. Parag. Med. Int [Internet]. 2020 [citado 06/06/2021]; 7(1): 66-76. Disponible en: http://scielo.iics.una.py/scielo.php?pid=S2312-38932020000100066&script=sci_abstract&tlng=es

11. Coughlin SS. Epidemiology of Breast Cancer in Women. Adv Exp Med Biol [Internet]. 2019 [citado 06/06/2021]; 1152: 9-29. Disponible en: https://link.springer.com/chapter/10.1007%2F978-3-030-20301-6_2

12. Park YMM, Bookwalter DB, O´Brien KM, Jackson CL, Weinberg CR, Sandler DP. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Annals of Oncology [Internet]. 2020 [citado 06/06/2021]; 32(3): 351-9. Disponible en: https://doi.org/10.1016/j.annonc.2020.12.008

13. Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep [Internet]. 2017 [citado citado 06/06/2021]; 7(44877): [aprox. 10 pp.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357949/

14. Lunkman Anwar S, Cahyono R, Prabowo D, Surya Avanti W, Choridah L, Kus Dwianingsih E, et al. Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors. BMC Cancer [Internet]. 2021 [citado 06/06/2021]; 21(2021):590. Disponible en: https://doi.org/10.1186/s12885-021-08343-0

15. Mathews Samuel S, Varghese E, Varghese S, Büsselberg D. Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treatment Review [Internet]. 2018 [citado 06/06/2021]; 70: 98-111. Disponible en: https://doi.org/10.1016/j.ctrv.2018.08.00

16. Maffuz-Aziz A, Labastida-Almendaro S, Espejo-Fonseca A, Rodríguez-Cuevas S. Características clinicopatológicas del cáncer de mama en una población de mujeres en México. Cirugía y Cirujanos [Internet]. 2017 [citado 06/06/2021]; 85(3): 201-7. Disponible en: https://www.elsevier.es/es-revista-cirugia-cirujanos-139-articulo-caracteristicas-clinicopatologicas-del-cancer-mama-S000974111630069X

Downloads

Published

2021-10-30

How to Cite

1.
de Armas Hernández Y, Hernández Frómeta M, Peñate Delgado R, Roque Acanda K, Zaldivar Garit I, Germán Flores L. Clinical and tumoral characteristics of diabetic patients with breast cancer. Rev Ciencias Médicas [Internet]. 2021 Oct. 30 [cited 2025 Sep. 12];25(5):e5236. Available from: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/5236

Issue

Vol. 25 No. 5 (2021)

Section

ORIGINAL ARTICLES

License

Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.

Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/